Presented by Deanna Mudie, Ph.D., Principal Scientist, and Aaron Stewart, M.S., Associate Principal Scientist.
Amorphous solid dispersions (ASDs) are an important technology for improving oral absorption of poorly water-soluble drugs. To achieve robust ASD drug products pharmaceutical scientists must design ASD formulations to attain several key attributes including in vivo performance, stability and manufacturability while minimizing dosage form size. Combining knowledge of key drug, polymer and gastrointestinal properties together with an in vitro and in silico toolkit is critical for achieving key attributes while reducing development timelines and drug substance requirements. This webinar highlights Lonza’s best practices for streamlined development of ASD drug products using traditional and novel formulation architectures.
Key Learning Objectives:
- Learn how Lonza’s custom and off-the-shelf in vitro and in silico tools can be combined to streamline ASD formulation development
- Gain knowledge about how drug and polymer properties, drug loading and dosage form architecture can influence ASD in vitro and in vivo performance
- Learn how to maximize drug loading in ASD dosage forms while still achieving good performance, stability and manufacturability